Viral Vectors And Plasmid DNA Market Report 2026

Viral Vectors And Plasmid DNA Market Overview

• Viral Vectors And Plasmid DNA market size has reached to $1.38 billion in 2025 • Expected to grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 6.6% • Growth Driver: Rising Tuberculosis Incidence Fuels Viral Vector And Plasmid DNA Market • Market Trend: Innovative Helper Plasmids Enhance The Viral Vectors And Plasmid DNA Market • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Viral Vectors And Plasmid DNA Market?

Viral vectors refer to a tool made of a viral genome that has been converted into a plasmid-based technology, modified for safety by deleting several necessary genes, and the viral components have been separated. Whereas, Plasmid DNA refers to a tiny, circular DNA molecule that can be found in some bacteria and other tiny organisms. Physically distinct from chromosomal DNA, plasmids multiply on their own. The main types of products in viral vectors & plasmid DNA are plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that is different from the chromosomal DNA of a cell. Plasmids are found organically in bacterial cells as well as in certain eukaryotes. Plasmid genes frequently confer genetic benefits to bacteria, such as antibiotic resistance. The different diseases include infectious diseases, genetic disorders, cancer, and others, and are used in gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The several sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies.

What Is The Viral Vectors And Plasmid DNA Market Growth Forecast?

The viral vectors and plasmid dna market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to development of clinical-grade and gmp plasmid dna, expansion of viral vector applications in cancer and infectious diseases, rising investment in gene therapy, growing demand for immunotherapy solutions, adoption of novel vector platforms such as aav and lentiviral vectors. Major trends in the forecast period include rising adoption of plasmid dna and viral vectors in gene therapy, expansion of viral vector platforms for cancer and genetic disorder treatments, growth in gmp-grade plasmid dna production for clinical applications, increasing research on novel adeno-associated and lentiviral vectors, integration of plasmid dna and viral vectors in immunotherapy and vaccine development.

Global Viral Vectors And Plasmid DNA Market Segmentation

1) By Product: Plasmid DNA, Viral Vectors 2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases 3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications 4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies Subsegments: 1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA 2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

What Is The Driver Of The Viral Vectors And Plasmid DNA Market?

The increasing incidence of tuberculosis cases is expected to propel the growth of the viral vector and plasmid DNA market going forward. Tuberculosis (TB) is a contagious and potentially serious infectious disease caused by bacteria. It primarily affects the lungs but can also impact other parts of the body. Plasmid DNA vaccines have been used to deliver microbial antigen-coding genes for tuberculosis. These vaccines can be designed to express specific antigens of Mycobacterium tuberculosis, the bacterium that causes tuberculosis and can be administered through intramuscular injection. For instance, in February 2024, according to the GOV.UK, a UK-based government department, Cases of tuberculosis (TB) in England increased by 10.7% in 2023, rising from 4,380 in 2022 to 4,850. Therefore, the increasing incidence of tuberculosis cases is driving the growth of the viral vector and plasmid DNA market.

Key Players In The Global Viral Vectors And Plasmid DNA Market

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, Каnеkа Соrроrаtіоn, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Global Viral Vectors And Plasmid DNA Market Trends and Insights

Major companies operating in the viral vectors and plasmid DNA market are increasing their focus on introducing innovative products, such as helper plasmids, to gain a competitive edge in the market. A helper plasmid is a type of plasmid DNA that is used in the production of viral vectors, including adeno-associated viral vectors (AAV), which are commonly used in gene therapy. For instance, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, launched off-the-shelf pHelper, a helper plasmid that aims to speed up the process from early discovery through commercial manufacture of adeno-associated virus (AAV)-based gene therapy programs and secure supplies. The newest of a broad range of contract development and manufacturing organization (CDMO) goods and services, helper plasmids are designed to protect viral vector packaging in cell and gene therapy operations and streamline convoluted supply chains. Adeno-associated viral vectors (AAV), which are frequently utilized in gene therapy, are created using helper plasmids.

What Are Latest Mergers And Acquisitions In The Viral Vectors And Plasmid DNA Market?

In January 2023, Moderna Inc., a US-based pharmaceutical and biotechnology company, acquired OriCiro Genomics for $85 million. This acquisition will accelerate pipeline development for Moderna by providing better tools for plasmid DNA synthesis and amplification, 'a key building block' for the production of messenger RNA, or mRNA. OriCiro Genomics is a Japan-based genome technology company that develops and commercializes cell-free systems for the assembly and amplification of circular DNA molecules, including plasmids and viral vectors.

Regional Insights

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Viral Vectors And Plasmid DNA Market?

The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Viral Vectors And Plasmid DNA Market Report 2026?

The viral vectors and plasmid dna market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors and plasmid dna industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.